Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

Abstract titles reveal some of ASCO’s key datasets.

The latest first-in-human trial entrants include several novel mechanisms, a PSMA radioconjugate and a new pan-KRAS challenger.

Ideaya and GSK join Novartis and Roche in the Werner helicase inhibitor race.

But Repare and Black Diamond still have rebuilding to do.